Drug Trial Radar · NCT07066657
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
572
Planned (sponsor's estimate)
Start
Jul 25, 2025
Primary completion
Mar 2028
Study completion Dec 2030
Sponsor
- Lead sponsor
- ArriVent BioPharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Lepu Biopharma Co., Ltd.
- First posted
- Jul 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.
Conditions
- Locally Advanced or Metastatic Solid Tumors
- Colorectal Cancer
- Gastric Cancer
- Pancreatic Cancer
Interventions
MRG007Drug
MRG007 will be administrated as specified in the protocol.
MRG007 and BevacizumabDrug
MRG007 will be administered as specified in the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicity (DLT) - Phase IaTime frame: Baseline to Day 21 of the first treatment cycle
- Serious Adverse Events (SAEs)Time frame: Baseline to 30 days after the last dose of study treatment
- Treatment-Emergent Adverse Event (TEAE)Time frame: Baseline to 30 days after the last dose of study treatment
- Treatment-Related Adverse EventTime frame: Baseline to 30 days after the last dose of study treatment
- Objective Response Rate (ORR) as assessed by investigator - Phase IbTime frame: Baseline to study completion (up to 24 months)
Locations
21 sites in 2 countries. Site status is shown where the registry gives one.
ULCA
Los Angeles, California · Recruiting
UCSF
San Francisco, California · Recruiting
University of Colorado
Aurora, Colorado · Recruiting
Sarah Cannon Research Institute
Denver, Colorado · Recruiting
Sarah Cannon Research Institute
Sarasota, Florida · Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
NEXT Dallas
Irving, Texas · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Peking University Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Beijing Gobroad Hospital
Beijing, Beijing Municipality, China · Recruiting
Chongqing Daping Hospital
Chongqing, Chongqing Municipality, China · Recruiting
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Zhejiang, Hangzhou, China · Recruiting
Harbin Medical University Cancer Hospital
Heilongjiang, Harbin, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
Cancer Hospital of Shandong First Medical University
Shandong, Jinan, China · Recruiting
Renji Hospital Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.